Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

ANI

Drug and asset intelligence for ANI with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Sponsor company

RegulatoryAugust 3, 2026

ANI Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Leucovorin Calcium.

RegulatoryJune 24, 2026

ANI Pharmaceuticals has submitted a supplemental application for a combination product containing Oxycodone and Aspirin.

No catalysts indexed for this entity yet.

No catalysts indexed for this entity yet.

No related entities indexed yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.